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Abstract
Background: The introduction of paediatric palliative care and referral to specialised teams still occurs late in the
illness trajectory of children with life-limiting diseases. The aim of this ongoing multipart study was to develop a
screening instrument for paediatricians that would improve the timely identification of children who could benefit
from a palliative care approach.
Methods: We used a qualitative study approach with semi-structured interviews (Part 1) and a focus group
discussion (Part 2) to define the domains and items of the screening instrument. Seven international paediatric
palliative care experts from the UK, France, USA, and Canada took part in face-to-face interviews, and eleven
paediatric health professionals from the University Children’s Hospital, Zurich, participated in a subsequent focus
group discussion.
Results: This preliminary phase of development and validation of the instrument revealed five domains relevant to
identifying children with life-limiting diseases, who could benefit from palliative care: 1) trajectory of disease and
impact on daily activities of the child; 2) expected outcome of disease-directed treatment and burden of treatment;
3) symptom and problem burden; 4) preferences of patient, parents or healthcare professional; and 5) estimated life
expectancy. Where palliative care seems to be necessary, it would be introduced in a stepwise or graduated
manner.
Conclusions: This study is a preliminary report of the development of an instrument to facilitate timely
introduction of palliative care in the illness trajectory of a severely ill child. The instrument demonstrated early
validity and was evaluated as being a valuable approach towards effective paediatric palliative care.
Keywords: Palliative care, Children, Family, Assessment, Needs
Background
To be effective, paediatric palliative care (PPC) should be
integrated into other aspects of paediatrics [1,2]. A num-
ber of studies [2-4] have clarified the needs of children
and their families once the child’s disease becomes incur-
able and progressive; they include symptom management,
information, relationship with and access to health profes-
sionals, and participation in decision-making. PPC can
address these; it is typically delivered through a shared
care model, in which the PPC team works alongside pri-
mary attending professionals [1,5,6]. The effectiveness of
this approach has been shown [6,7], but access to PPC is
still limited in some first world countries, most notably in
Switzerland. Recent reports [8-10] show that, despite
WHO guidelines [11], referrals to palliative care are often
made late in the trajectory of a life-limiting disease. This is
true even in countries like the UK, where availability of
palliative care for children is comparatively good [12-14].
Referral patterns remain less than ideal despite the
availability of a number of scales designed to improve
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recognition of the need for palliative care [15-19], perhaps
because they are all designed for adults.
Several factors may contribute to this delay. The poten-
tial benefits of PPC may be overlooked early in the trajec-
tory of a condition, especially if the likelihood of control
or cure is overestimated [20-22]. For some professionals,
death is perceived as a failure of care so that they are re-
luctant to consider its possibility or proximity [23]. Some
professionals are concerned about the term ‘palliative care’
itself [24,25], feeling its interpretation by families may be
negative. Finally, professionals may feel under pressure
from families to offer treatments that are futile because
for some families any alternative is equivalent to ‘giving
up’ [26].
The effect of these misunderstandings can be exacer-
bated by the fact that knowledge and understanding of
PPC are often inconsistent [22] and that there are few
clear criteria of when PPC should be introduced [20,27].
In adults, the focus of instruments for helping prognosti-
cation is on estimating life expectancy, and their use often
relates specifically to decision-making around end-of-life
issues. In children, by contrast, a palliative care approach
can have more diverse aims, reducing burdensome treat-
ments in children suffering from advanced cancer, enhan-
cing quality of life through effective symptom control and
easing the emotional burden on parents and the family.
To achieve these aims, an instrument for children must
capture the child’s palliative care needs at an earlier stage
than those used in adults [15,16].
We have developed a model for an instrument, called
Paediatric Palliative Screening Scale (PaPaS Scale) that is
designed to help identify children who would benefit from
PPC in order to facilitate timely and appropriate referral.
Aims
The overall aim of the project is to develop a tool to facili-
tate appropriate and timely involvement of specialist PPC
services in the care of patients. The aims of this initial de-
velopment phase were: 1) to determine which elements
identify children requiring PPC; and 2) to show face and
content validity of the items.
Methods
Design
This study is the initial development phase of a larger pro-
ject (Figure 1) whose aim is to provide a clinical tool that
will facilitate appropriate and timely referral to specialist
PPC services. We used an established method [28] that
comprises three stages.
1. Development of a conceptual model on the basis of
published evidence and the authors’ personal
experiences.
2. Description of further items on the basis of expert
interviews and a focus group discussion that included
providers and users of specialist palliative care.
3. Preliminary testing for face and content validity.
Model for the instrument
The basis of the model (Version 1 of the instrument;
Table 1) was the initial model, based on published evi-
dence from a literature review on characteristics of
Figure 1 Flowchart of the study.
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children with PPC needs. Neonates and infants (<12
months) were excluded as their disease trajectories and
needs are different [29]. The instrument had to accommo-
date considerable heterogeneity, since PPC encompasses
the needs of patients with a wide range of ages (≥1 to ≤19
years) and of diagnoses. The term ‘life-limiting’ is defined
in palliative care by the Together for Short Lives Categor-
ies (TfSL, formerly ACT [5]; Table 2). The search was
extended to include literature on adults as well as on chil-
dren, from four databases (PubMed, EMBASE, CINHAL,
Google Scholar) using the following keywords: ‘paediatric
palliative care’, ‘hospice’, ‘assessment’ and ‘needs assessment’
(health service needs and demand). Information was
extracted on definitions of PPC, categories of palliative pa-
tients, the specific palliative needs of patients and families,
prognostic indicators, and illness trajectories. On the basis
of these studies, five domains were considered by the
investigators (EB, JP) to be relevant to developing the
model:
1. Estimated life expectancy
2. Expected outcome of treatment directed at the disease
3. Performance status,
4. Symptom and problem burden
5. Preferences of patient, family or healthcare
professional.
Each domain was further divided into two to five ques-
tions (items) for a total of 13 items. Each item provided at
least two choices (scored 0–4). Higher individual or total
scores indicate a greater need for PPC.
In clinical practice, the decision to refer an individual
child to palliative care is often made in a way that is grad-
uated, rather than in a single moment, and this is reflected
in the model by considering the process conceptually in
three steps (Figure 2):
1. Introduction of Palliative Care – consider
introducing the concept of PPC
2. Palliative Care Approach – basic symptom
management alongside treatments to control the
disease
3. Palliative Care Focus – PPC becomes the focus of care.
Setting/participants
Phase 1-expert interviews
The semi-structured interviews with PPC experts included
a reflection on the definition of PPC and how they identi-
fied children with PPC needs. This was followed by the
introduction of the instrument (Version 1; Table 1 and
Figure 2) and the invitation to provide preliminary qualita-
tive evaluations of face and content validity [30]. Face valid-
ity relies on whether the instrument looks like it measures
what it was intended to measure. Content validity describes
whether the chosen items of an instrument are representa-
tive for the concept of the instrument (in our case
intending to measure palliative care needs of children). The
opinions of experts are used to evaluate face and content
validity in an early stage of instrument development.
The participants were purposively selected specialist
practitioners in PPC. Practitioners were invited on the
basis of their clinical leadership in their country, region,
academic institution or organisation. They included
five paediatricians (aged 45–59) and two nurses (ages 47-
58yrs) from the United Kingdom, France, the United
States and Canada. Before becoming a full-time PPC ex-
pert, the participants had worked in oncology, intensive
care, neurology and general paediatrics.
The interviews were conducted by the principal investi-
gator (EB) between June and September 2008. They were
recorded digitally and transcribed verbatim. The tran-
scripts were coded by hand using qualitative content
analysis in which consensus-finding final themes and sub-
themes were identified by two investigators (EB, JP). Illus-
trative quotations were extracted [31]. Data from this first
phase were used to modify the instrument (Version 2;
Table 3) and as the basis for developing the structured
interview for the focus group discussion.
Phase 2-focus group discussion
Phase 2 further explored the face and content validity of
Version 2 of the instrument with a group of paediatric gen-
eralists and sub-specialists from the University Children’s
Hospital Zurich. This provided input from potential users
of the instrument but who were outside specialist PPC
[32]. The instrument was translated into German (EB) to
complement the original English version. Eleven partici-
pants (4 physicians, 3 nurses, 2 social workers, 1 psycholo-
gist, and 1 physiotherapist) were selected purposively
and represented a broad spectrum of sub-specialties
(cardiology, intensive care, neurology, and oncology).
All participants had long professional experience (10-35yrs;
median 17yrs) and all included among their patients
some whose condition could not be cured. The focus
group discussion was facilitated by the principal investi-
gator (EB), and recorded by means of contemporaneous
notes made by a research assistant, which were then
verified by participants.
The study was approved by the Ethics Review Board
(University Children’s Hospital, Zurich). All participants
provided written consent.
Results
Phase 1
General themes
Definition of PPC Participants were supportive of the
three most commonly used definitions (World Health
Organisation, WHO [11]; Together for Short Lives,
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Table 1 Version 1 of the PaPaS Scale
Domain
and Item
number
Item Characteristic Score
(preliminary)
Changes made to Version 1
Domain 1 Estimated life expectancy Position: end of the scale
1.1 Estimated life expectancy > 2 years 0 Qualitative time frames (e.g. weeks
to months)
> 1 but < 2 years 1
3 months to 1 year 2
< 3 months 3
1.2 “Would you be surprised if
this patient were still alive
in 6 months time?”
Yes 3
No 0
Domain 2 Expected outcome of current treatment directed at the disease and
burden of this treatment
2.1 Expected outcome of
treatment directed at the
disease
There are no treatments currently that can cure
the disease or prolong life.
4 Percentages omitted Outcome of
treatment described with respect to life
extension and quality of life
Current treatment patient is receiving or will be
receiving may, in only a small number of cases
(<20%), prolong life but will not cure.
3
Current treatment patient is receiving or will be
receiving may, in >20% of cases, prolong life but
will not cure.
2
Current treatment patient is receiving or will be
receiving may cure the illness in <20% of cases.
1
Current treatment patient is receiving or will be
receiving may cure the illness in >20% of cases.
0
2.2 Burden of treatments Treatments carry a high level of burden (many
side effects).
2 Further explication of ‘burden’ (e.g. side
effects, stay in hospital)
Treatments carry a low to medium level of
burden (few side effects).
1
Treatments carry no or minimal burden (side
effects) or no treatment is envisioned.
0
Domain 3 Performance status Rephrased: ‘Trajectory of disease and
impact on daily activities of the child’
Position: beginning of the scale
3.1 Current performance status
(in comparison with the
child’s own baseline)
Moderate to severe restriction of play (no active
play, requires assistance for quiet play) 0-40% of
normal range.
3 Change of characteristics and omission
of percentages
Mild to moderate restriction of play (able to
engage in some active play; requires assistance)
50-70% of normal range.
1
Normal range of play (able to carry on usual play
activities) 80-100% of normal range.
0
3.2 Rate of decline of
performance status
Overall, performance has decreased by half over
the last 4 weeks.
2 Time frame and impact of decline
included in 3.1
Overall, performance has decreased by about a
third over the last 4 weeks.
1
Overall performance has not deteriorated over
the last 4 weeks.
0
Domain 4 Symptom and problem burden
4.1 Number of symptoms Patient has 3 or more symptoms (e.g. pain,
weight loss, fatigue, dyspnoea, nausea &
vomiting, depression, anxiety)
4 List of symptoms amended
Patient has 2 symptoms 3
Patient has 1 symptom 2
Patient is asymptomatic 0
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formerly ACT [5]; and American Academy of Pediatrics
[33]). The definitions were felt to be broad and relatively
non-specific. Participants acknowledged that although
they were inclusive and accommodated the complexity in-
herent in PPC, they also lacked precise definition, which
potentially made them unsuitable in discussions with
healthcare managers or politicians. Furthermore, they do
not provide guidance in respect of when to introduce PPC
in an individual patient.
I wouldn't change those. […] it means that palliative
care begins quite early and goes on quite far. […] when
we see the consequences of life-threatening illness on
the family it is palliative care.
Table 1 Version 1 of the PaPaS Scale (Continued)
4.2 Symptom intensity Any symptom is severe (equivalent to
>6 out of 10)
3 Intensity amended by controllability
Any symptom is moderate (equivalent to
4–6 out of 10)
2
Any symptom is mild (equivalent to 3 or
less out of 10)
1
Symptoms are absent 0
4.3 Psychological distress
of patient
Significant 2
Mild to moderate 1
Absent 0
4.4 Psychological distress
of parent(s)
Significant 2
Mild to moderate 1
Absent 0
4.5 Psychological distress
of siblings
Significant 2 Omission
Mild to moderate 1
Absent 0
Domain 5 Preferences of patient, family and health professional
5.1 Request by patient
and family
Patient specifically requests a palliative
care approach.
4 Yes Omission
0 No
Family specifically requests a palliative
care approach.
4 Yes
0 No
5.2 Preference of health
professional
You feel that this patient would definitely benefit
from a palliative care approach.
4 Yes
0 No
Total score:
Table 2 Diagnostic groups qualifying for palliative care (according to Together for Short Lives, formerly ACT) [5]
Category Examples
Group 1
Life-threatening conditions for which curative treatment may be feasible but can fail. Cancer, heart defects, irreversible organ failures
Group 2
Conditions where premature death is inevitable. Treatment may aim at prolonging life and allowing
normal activities.
Cystic fibrosis, Duchenne muscular dystrophy
Group 3
Progressive conditions without curative treatment options. Exclusively palliative treatment may
extend over many years.
Metabolic disorders, neuromuscular diseases
Group 4
Irreversible but non-progressive conditions causing severe disabilities leading to susceptibility to
health complications and likelihood of premature death.
Severe cerebral palsy
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[…] what it doesn't do all by itself is to dictate how
that should be done. It says what palliative care is but
it doesn't make some first steps in order to say how
that should be worked out practically.
When to initiate PPC? The most appropriate point at
which PPC should be introduced in the care of a child
was viewed as being individual to the patient, and as de-
pending on a number of factors, including the anticipated
prognosis, any life-threatening events within the context
of a complex chronic condition, worsening of symptoms,
and increasing needs of patients and families. Availability
of services locally was also seen to be an influential factor.
Most participants underscored the importance of flexibil-
ity in considering the optimum time to initiate a discus-
sion with parents about starting PPC.
I also differentiate between kids with complex
chronic conditions and those who have a life-
threatening component to their complex chronic
condition. […] usually the trigger is a life-threatening
event or a decision around an intervention of a
symptom crisis.
I think when there is a significant risk that the child
will not survive. The hard part is, what does that
mean? Survive for how long? […] this may not be this
hospitalisation it may be the future.
Could a screening instrument be useful? Most partici-
pants felt an instrument for facilitating timely and appro-
priate involvement of PPC would be a valuable tool for
improving care of children with life-limiting conditions in
clinical practice. Potential benefits identified by participants
included screening for appropriate patients, supporting the
decision-making process at the end of life, and education of
professional colleagues.
[…] it is extremely valuable. […] In practice we need to
deal with people who need to know just palliative care,
is it necessary or not. […] What you are doing is
saying this particular child, irrespective of the
diagnosis, is getting to a point where they need it. […]
It exactly addresses the difficulty of applying a
philosophy in practice.
I see that as an educational opportunity. […] and
reframing of what palliative care can offer. […] A tool
that enables sort of a better understanding of how a
palliative care programme can help would be very,
very helpful.
I think it’s a good idea. Because I think often we are
asked, you know “when should we call you” or nurses
or chaplains are saying it and the team is saying “not
yet”, so I think it’s a good thing. […] Some sort of
instrument like that would both help teach clinicians
what palliative care is, and then perhaps help them
think about when to use it […].
Instrument-specific themes (version 1)
All participants agreed that the five domains that had been
identified were important and appropriate, but there were
Figure 2 Stepwise approach (Version 1 of the instrument).
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Table 3 Version 2 of the PaPaS Scale
Domain
and Item
numbers
Item Characteristic Score Changes made to Version 2
Domain 1 Trajectory of disease and impact on daily activities of the child
1.1 Trajectory of disease and impact on daily activities of the
child (in comparison with the child’s own baseline) (with
reference to the last 4 weeks up to a few months)
Stable 0 Time frame: 4 weeks,
Characteristics: unified, Amended:
increase of hospital admissionsSlowly deteriorating without
impact on daily activities.
1
Unstable with frequent
absences from school or
restriction of daily activities.
2
Significant and rapid
deterioration with severe
restriction of daily activities.
4
Domain 2 Expected outcome of treatment directed at the disease and burden of treatment
2.1 Treatment for the disease … does not cure and has no
effect on quality-of-life.
3 Meaning of ‘treatment’ outlined
further, Characteristics further
divided
… does not cure but has a
positive effect on survival and
quality-of-life.
2
… may cure or will prolong
survival significantly.
1
2.2 Burden of treatment, (Burden means side effects of
treatment as well as additional burdens such as stay in
hospital)
High level of burden 2
Low to medium level of
burden
1
No or minimal burden or no
treatment is envisioned.
0
Domain 3 Symptom and problem burden
3.1 Number of symptoms, (e.g. pain, dyspnoea, nausea/
vomiting, weakness/fatigue, anxiety/depression, weight
loss, neurological symptoms), (during the last 4 weeks)
≥ 3 symptoms 4 Number and listing of symptoms
replaced and summarised by
intensity and controllability2 symptoms
3
1 symptom 2
Patient is asymptomatic 0
3.2 Symptom intensity or difficulty of symptom control
estimation following VAS scale 0–10, (over the last 4
weeks)
Any symptom is severe
(equivalent to ≥6 out of 10)
3
Any symptom is moderate
(equivalent to 4–6 out of 10)
2
Any symptom is mild
(equivalent to≤ 3 out of 10)
1
Patient is asymptomatic 0
3.3 Psychological distress of patient due to symptoms Significant 2 Provisional change of scores
Mild to moderate 1
Absent 0
3.4 Psychological distress of parents or family due to
symptoms
Significant 2
Mild to moderate 1
Absent 0
Domain 4 Preferences of health professional
4.1 Preference of health care professional You feel that this patient
would definitely benefit from
palliative care.
4
Yes
Preference of patient and family
reintroduced counting only one
answer0
No
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some specific comments on each. Modifications resulting
from the expert interviews are listed in Table 1.
Domain 1: estimated life expectancy This domain pro-
vided the most controversy. Participants identified three
problems in considering life expectancy:
! It was deemed difficult to do accurately, and, in
addition, specific numbers could imply precise
prognosis.
! It would be preferable to replace numbers with
terms that were more obviously estimated (such as
‘days to weeks’ or ‘weeks to months’).
! There was a difficulty in relating the individual’s
life expectancy and the benefit of introducing
PPC.
Lots of people with life expectancy of more than 2
years have a bigger need for palliative care than ones
with a lesser expectancy. It’s wrong; there is something
wrong there. Alternatively: ‘life-limiting’, ‘life-
threatening’, ‘serious risk of death’.
I don’t think it plays a role […], if you have got a child
with spinal muscular atrophy that’s kind of very clear
that this child is not going to live more than may be two
years. […] a child with cerebral palsy – you got no idea.
Domain 2: expected outcome of current treatment
Participants agreed that this was an important domain.
Four main issues were discussed:
! The term ‘cure’ was perceived not to be applicable
in many life-limiting conditions, since they are
incurable from the outset. The terms ‘life-extension’
and ‘comfort’ were suggested as alternatives.
! The use of percentages to convey the likelihood of
cure was considered to be inappropriate since that
likelihood could often not be known with
precision.
! Integrating a question prompting the physician to
consider the balance between good versus harm, and
harm versus cure from a quality-of-life perspective
was suggested.
! The term ‘burden’ needed clarification, so that users
of the instrument understood its holistic scope,
including non-physical aspects such as impact on
discharge home or to a hospice.
‘Current treatments’ is absolutely important. […]
What is really good is expected outcome and burden
of treatments.
[…] very hard to apply […] it’s never about cure […]
it’s always about prolonging life […], the hope of this
treatment is to control the disease for as long as
possible.
[…] I would like to see ‘expected outcome of disease-
directed treatment’ […] and just a limited number of
choices: life extension, life extension along with
comfort, comfort alone.
Domain 3: performance status Participants agreed that
performance (functional) status was important, yet chal-
lenging. A description of the performance status that
applies to all children, including those with severe disabil-
ities, was felt to be elusive. To help grade the functional
decline, two suggestions were made:
! To include sentinel events, such as missing days in
the child’s school/education facility or an increase in
hospital admissions for symptom control.
! To rephrase ‘performance’ to a more comprehensive
term.
[…] this could be a good way to assess change. Ask
about change in frequency of hospitalisation.
Table 3 Version 2 of the PaPaS Scale (Continued)
Domain 5 Estimated life expectancy
5.1 Estimated life expectancy Several years 0 Change to an either-or-question
Months to 1–2 years 1
Weeks to months 2
Days to weeks 3
5.2 “Would you be surprised if this patient were still alive in 6
months time?”
Yes 3
No 0
Total score:
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[…] you have also given as much impact to change in
performance status as you have to their actual
performance status, which is very important, because
a child who can do virtually nothing may be so
precious to his or her parents.
Instead of ‘performance’, the disease progress could be
described as: ‘steady, unstable/changing or
deteriorating’ – this could also include change in
mobility.
Domain 4: symptom and problem burden Participants
agreed on this domain. Four main suggestions were
made to improve the items.
! The selection of symptoms was criticised as too
limiting.
! Qualitative aspects concerning symptom intensity,
such as controllability were suggested.
! The item ‘psychological distress’ (4.3) was unclear
regarding to whom it referred (child, family or
both).
! Family burden was seen as particularly pertinent;
however, siblings’ distress appeared difficult to
identify.
So distress of sibling […] – most of our doctors
wouldn't know. It depends on the family sometimes the
siblings are away. […] how do you measure the distress
of a sibling who is 5-years old?
Domain 5: request for PPC by patient, family, or
health professional This domain generated significant
discussion including two contrasting issues.
! It was felt to be very unusual for families to request
PPC.
! The question could be useful in that it might
prompt users to consider PPC.
! A request by a family member should carry
significant weight in terms of prompting the team to
introduce PPC.
[…] nobody is going to do that. […] I would say,
seriously, in about 10 years, you know, a handful
would actively ask. […] families will say “but let’s take
a chemo break”.
[…] some health professionals feel they [patients]
should benefit [from palliative care] and you have
weighted that quite appropriately, in my view highly. I
think it is very good.
[…] In my country, it's good to say “do people request
palliative care?” […] It is also a way of saying what do
they want and how do I - straight at the beginning -
try to organise things.
Stepwise approach The idea of a stepwise approach to
introducing PPC was supported with some suggestions
for modifications.
The first instruction is just to tell the family what
palliative care is or introduce the concept of mortality.
The second is to make out a plan […] talk about how
you are going to involve palliative care, and the third
[…] there we go, get to the phone and call them.
I think that’s quite good. Because it goes back to this
thing about parents starting this question “is my child
going to die in childhood?”.
Modification: The steps were rephrased (Figure 3).
Procedural issues of the instrument Some concern
was expressed that inexperienced clinicians might use it
inappropriately. Thus, two interviewees highlighted the
possibility of non-referral because of a low score, and
another emphasised that the most important aspect
about PPC would be to get in touch with the team in-
volved regardless of criteria or scores.
[…] even if the score is less than 25 there are some
situations in which you should nevertheless refer.
[…] if we were allowed to introduce what we do with
families, we would even have more consults. […] They
don't have to make the referral but call to discuss. […]
you are not going to bring up death […] you are going to
support families […] you are really going to enhance both
the team’s and the family’s coping and decision-making.
Phase 2
Instrument-specific themes (version 2)
In general, the concept of the instrument and the step-
wise approach were supported, and its clinical usefulness
was highlighted.
Domain 1: trajectory of disease and impact on daily
activities of the child Participants working with chil-
dren with neurological conditions highlighted the caveat
that some children compensate well for milder
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deteriorations but decompensate precipitously and dis-
proportionately at a certain point. Thus, a ‘rapid deteri-
oration’ did not seem to apply to many of these
children. It was also emphasised that the referring time
frame should be clearer.
Domain 2: expected outcome of treatment directed
at the disease and burden of treatment Further divid-
ing the characteristics of treatment and burden of treat-
ment, and also clarifying that treatment does not mean
disease-related complications such as pain or dyspnoea
were suggested.
Domain 3: symptom and problem burden Some par-
ticipants emphasised the difficulty of symptom assess-
ment in children and suggested eliminating it altogether.
There was consensus that the number of symptoms was
less relevant than the intensity and impact of the symp-
tom(s). For example, a child with heart failure or under
chemotherapy could experience ≥3 symptoms with or
without impact on daily living. In addition, psychological
distress caused by uncontrolled symptoms was thought
to be more important.
Domain 4: preference of health professionals In con-
trast to Phase 1, participants supported the inclusion of
the parents’ request for PPC. Consistent with Phase 1,
the misperceptions and misunderstandings about PPC
on the part of both professionals and families were
highlighted.
Domain 5: estimated life expectancy The majority of
participants deemed this element very important. How-
ever, it was felt that ‘life expectancy’ and the ‘surprise-
question’ represented the same entity and should there-
fore be aggregated into one single item.
These findings and modifications resulted in Version 3
of the instrument (Table 4).
Procedural issues of the instrument Similarly to Phase
1, uncertainty was expressed about who would use the
instrument (physician, parents or team), and who would
decide about further consequences.
Discussion
The need to initiate PPC in a timely fashion through im-
proved identification of children and adolescents who
might benefit has been highlighted [20,21]. This study es-
tablishes early face and content validity for a new instru-
ment to facilitate this identification in clinical practice.
The PaPaS Scale builds on the taxonomy of Together
for Short Lives, formerly ACT [5] and underscores that
PPC is not limited to end-of-life care. Neonates and in-
fants were excluded as their disease trajectories are
mostly short, two thirds of them dying during the first
weeks of life [29,34] on the neonatal intensive care unit
without episodes of being in their ‘natural’ environment,
the family’s home. Even if neonates constitute an import-
ant and numerically large proportion of children who
could benefit from PPC, they have different needs and
we decided not to include them.
The indicators proposed in our instrument opera-
tionalize in more detail the approach suggested by
Rushton et al. [6]. These authors recommended triggers to
identify patients for PPC-conferencing, including: 1) lim-
ited life span; 2) ‘surprise-question’ – sudden death within
6–12 months; 3) increase in hospitalisations during the
past 6–12 months; 4) major clinical events; 5) symptoms
that have changed the frequency of clinic visits; 6) change
in response to treatment; 7) conflicts about goals of care.
In our experts’ interviews three of these triggers (progno-
sis, events and symptoms) plus increasing needs of the
child and its family were brought up in the first part of the
interview, which included a spontaneous reflection on
how they identify children with PPC needs. However, with
respect to life expectancy (prognosis), the discussions were
highly controversial. While several experts of Phase 1 sug-
gested omitting this domain, participants of Phase 2
Figure 3 Stepwise approach (Version 2 of the instrument).
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Table 4 Version 3 of the PaPaS Scale
Domain and
Item
numbers
Item Characteristic Score
Domain 1 Trajectory of disease and impact on daily activities of the child
1.1 Trajectory of disease and impact on daily activities of the
child (in comparison with the child’s own baseline)
(with reference to the last 4 weeks)
Stable 0
Slowly deteriorating without impact on daily activities. 1
Unstable
With impact on and restriction of daily activities.
2
Significant deterioration with severe restriction of daily
activities.
4
1.2 Increase of hospital admissions, (> 50% within 3 months,
compared to previous periods)
No 0
Yes 3
Domain 2 Expected outcome of treatment directed at the disease and burden of treatment
2.1 Treatment directed at the disease,
(does not mean treatment of disease related complications,
such as pain, dyspnoea or fatigue)
…is curative. 0
…controls disease and prolongs life with good quality
of life.
1
…does not cure or control but has a positive effect on
quality of life.
2
…does not control and has no effect on quality of life. 4
2.2 Burden of treatment,
(Burden means side effects of treatment and additional
burdens such as stay in hospital in the patient’s or family’s
view)
No or minimal burden or no treatment is envisioned. 0
Low level of burden 1
Medium level of burden 2
High level of burden 4
Domain 3 Symptom and problem burden
3.1 Symptom intensity or difficulty of symptom control
(over the last 4 weeks)
Patient is asymptomatic 0
Symptom(s) are mild and easy to control 1
Any symptom is moderate and controllable 2
Any symptom is severe or difficult to control
(unplanned hospitalisation or outpatient visits,
symptom crises)
4
3.2 Psychological distress of patient related to symptoms Absent 0
Mild 1
Moderate 2
Significant 4
3.3 Psychological distress of parents or family related to
symptoms and suffering of the child
Absent 0
Mild 1
Moderate 2
Significant 4
Domain 4 Preferences/needs of patient or parents
Preferences of health professional
4.1 Patient/parents wish to receive palliative care or formulate
needs that are best met by palliative care.
No 0 please
answer 4.2
Yes 4 do not
answer 4.2
4.2 You/your team feel that this patient would benefit from
palliative care.
No 0
Yes 4
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strongly voted to keep it as it seemed important that this
question receives more attention in decision-making. This
controversy is interesting; it may reflect cultural
differences or the various stages of national PPC achieve-
ments, - particularly in Switzerland where PPC is only
starting to develop and to be recognized. Thus, in
Switzerland, life expectancy may play a stronger role in
decision-making towards the introduction of palliative
care as compared to UK, the US or Canada where PPC
starts to be integrated into care earlier in the course of a
disease [20,27].
Predictive factors and events focusing on the diagnosis
of dying have also been evaluated by others [34,35].
Brook and Hain [35] proposed that the following candi-
date factors be included in future studies: frequency of
hospital or intensive care admission, episodes of acute
illness without recovery to the child’s usual best level of
health and physiological changes such as decreased oral
intake. Feudtner et al. developed a paediatric mortality
prediction model to analyse the likelihood of death dur-
ing hospitalisation or 1-year post discharge [34]. Among
several predictors, the frequency of hospitalisations (>3)
during the year before the index hospitalisation and the
risk of death were strongly associated. Increase of
hospitalisations was also emphasised by some experts
from our study and was therefore included in Version 3
of the instrument.
The suggestion by some participants to exclude the
domain on preferences of the patient and the family was
surprising. This may reflect the difficulties that clinicians
(and parents) experience in halting treatment that is fu-
tile from a medical perspective. A recent study [36], for
example, found that more than a third of children with
cancer continued to receive cancer-directed treatment
after the parents had realised that there was no realistic
chance of cure. However, parents who felt that their
child had suffered due to cancer treatment prior to
death were particularly unlikely to recommend such a
treatment to other families. Our instrument could facili-
tate such a discussion by a broader exploration of the
child’s situation, suffering and needs.
Some reservations concerning the instrument were
expressed. There was scepticism about the extent to
which clinicians would use the instrument. The chal-
lenges in assessing presence and severity of symptoms in
children, or estimating life expectancy were highlighted.
Written instructions and appropriate training on how to
use the instrument will solve some of these concerns.
Notwithstanding these, it was felt that the instrument
could be a useful clinical and educational tool, increasing
earlier activation of PPC and heightening awareness of
palliative care needs amongst health professionals. The
educational aspect of the tool was particularly seen in
the fact that the use of the instrument would evoke dis-
cussions which may clarify what palliative care can add
in the care of an individual child and its family, and thus
translate the definition of palliative care into daily clin-
ical work with severely ill children. Our study suggests a
potential role for developing a scoring system linked to
this stepwise approach. The predictive validity and clin-
ical effectiveness (impact on children’s quality of life) of
such a system will need to be shown.
There are several limitations. This is only the first
phase in the development of a new instrument. The
interviewer (EB) was also the person who developed the
model and analysed the data, thereby potentially intro-
ducing bias. The discussions with the supervisor (JP)
during the development of the instrument’s model and
following the interviews and focus group for checking
final themes and sub-themes of data analysis should
have reduced the impact of this. The focus group in-
cluded only clinicians from a German-speaking Swiss
hospital, which affects the generalizability of the results.
However, testing in different settings and countries is
Table 4 Version 3 of the PaPaS Scale (Continued)
Domain 5 Estimated life expectancy
5.1 Estimated life expectancy Several years 0 please
answer 5.2
Months to 1–2 years 1 please
answer 5.2
Weeks to months 3 do not
answer 5.2
Days to weeks 4 do not
answer 5.2
5.2 “Would you be surprised if this child were to suddenly die in
6 months time?”
Yes 0
No 2
Total score:
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planned. In addition, the perspective of affected families,
particularly parents, has not been incorporated yet. This
is planned for the following steps of the instrument’s
validation.
Conclusions
The challenges of activating PPC earlier in the illness
trajectories of paediatric patients are highlighted. The
PaPaS Scale is a new instrument that shows some early
promise as an aid in identifying children and adolescents
who could benefit from PPC, without undermining
treatments to control the disease. Obviously, the results
of this study still represent preliminary work.
Future research
We plan additional psychometric testing; the next step
includes a series of case vignettes to further test the
items of the instrument, which will be followed by test-
ing with real patients (Figure 1). The educational role of
the instrument in terms of raising awareness of PPC
needs in children will also be evaluated in a later phase.
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